Skip to main
ELMD

Electromed (ELMD) Stock Forecast & Price Target

Electromed (ELMD) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Electromed Inc. demonstrated robust homecare revenue growth of 14.8% to $14.1 million, driven by enhanced sales rep productivity and effective demand generation initiatives. The company has established a solid foothold in the domestic homecare market, with distributor and hospital sales increasing significantly by 41% and 52%, respectively, indicating strong market traction. Although SG&A expenses rose by 17.2% due to strategic investments in personnel to bolster sales, marketing, and reimbursement efforts, these expenditures reflect a commitment to long-term growth and expansion into acute and international markets.

Bears say

Electromed Inc. faces a challenging outlook due to margin compression, competitive pressures, and decreased productivity among sales representatives, which could hinder growth potential. Additionally, any delays in the anticipated contributions from Pain Management and Wound Care could adversely affect expected growth rates and profit margins. These factors, combined with a significant decline in share price from a high of $35.43 to around $18, underscore the vulnerability of Electromed's financial performance.

Electromed (ELMD) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Electromed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Electromed (ELMD) Forecast

Analysts have given Electromed (ELMD) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Electromed (ELMD) has a Strong Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Electromed (ELMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.